malignant mesothelioma (mMS) - 1st line (L1) | |
malignant mesothelioma (mMS) - 1st line (L1) | |
nivolumab plus ipilimumab | CheckMate 743 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -